Febuxostat 40 mg daily appears to be as efficacious as allopurinol in lowering serum uric acid levels. [38] Both febuxostat 40 and 80 mg can be given to patients with mild-to-moderate renal impairment ...

Learn everything you need to know about Febuxostat-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Febuxostat is a xanthine oxidase (XO) inhibitor, prescribed for gout and hyperuricemia (high level of uric acid in blood). The serum concentration of the active metabolites of Ambroxol acefyllinate ...

(UPDATED) Despite worries over a potential CV risk with febuxostat, there is indeed a population of patients with gout for whom the risk-benefit profile is favorable for the treatment of hyperuricemia ...

The comparative efficacy of these therapies has been extended to patients with stage 3 chronic kidney disease, a common comorbidity in gout. Allopurinol and febuxostat are similarly effective in ...

Six weeks after hosting a joint meeting of its Arthritis Advisory and Drug Safety and Risk Management Advisory Committees to review cardiovascular risk signals, the US Food and Drug Administration has ...

Hyperuricemia in patients with gout is most commonly treated with allopurinol. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, could potentially be a therapeutic alternative for ...

Credit: Getty Images Major effects of febuxostat on renal outcome might be uric acid dependent, according to investigators. Beside reducing serum uric acid in patients with chronic kidney disease (CKD ...

The efficacy and safety of febuxostat was noninferior to allopurinol for preventing tumor lysis syndrome (TLS) in patients with malignant tumors about to receive chemotherapy, according to a new study ...

To the Editor: The article by Becker et al. (Dec. 8 issue) 1 includes an inaccurate and misleading statement regarding the comparison of 80 mg per day of febuxostat with allopurinol for gout. The ...

Am J Health Syst Pharm. 2011;68(5):389-398. As a xanthine oxidase inhibitor, febuxostat may interact with drugs that are metabolized by xanthine oxidase. Febuxostat is currently contraindicated in ...